Full Press Release Details
Reports First Quarter 2022 Financial Results
First quarter 2022 revenue increased 48% YoY
Company launched two new consumer OTC products
using its HYDROGEL Technology: The MEDAGEL ClearComfort Hydrogel Patch and The MEDAGEL Bug Bite Relief Patch
LANGHORNE, Pa. - May 12, 2022 -
NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle,
high-water-content hydrogel products for healthcare and consumer applications, today announced its financial results for the first quarter
ended March 31, 2022.
Adam Levy, NEXGEL Chief Executive Officer, commented,
"We are pleased with our financial results for the quarter. We have remained focused on our growth strategy within each of our
core business segments - branded products, contract manufacturing, and medical devices. Our consumer segment had a strong start to the
year with the launch of two new OTC products, The MEDAGEL ClearComfort Hydrogel Patch and The MEDAGEL Bug Bite Relief Patch. MEDAGEL
now has 10 SKUs available on Amazon, and the products continue to be a steady contributor to our revenue growth. In our contract manufacturing
segment, we are making progress on growing the business through our new offering that allows OTC brands to leverage our hydrogel products
for line extensions for their products. We are making progress with this strategy and are focused on expanding the business. Lastly,
we remain committed our medical device segment and continue to make advancements on our first product, NEXDrape, which is in the research
and development phase. We expect our revenue growth year-over-year trend to continue for the foreseeable future."
First Quarter 2022 Financial Highlights
Revenue for the three months ended March 31,
2022, was $396 thousand, an increase of $129 thousand, or 48%, when compared to $267 thousand for the three months ended March 31, 2021.
The increase in our overall revenue was due to sales growth of new products as well as our initiatives in branded consumer products.
Gross loss for the first quarter of 2022 was
$22 thousand, compared to a gross loss of $42 thousand for the three months ended March 31, 2021.
Cost of revenues increased by $109 thousand,
or 35%, to $418 thousand for the three months ended March 31, 2022, as compared to $309 thousand for the three months ended March 31,
2021. The increase in cost of revenues is primarily aligned with the new product line growth in the current year.
Operating expenses, including research and development
and selling, general and administrative expenses, increased by $312 thousand to $790 thousand for the three months ended March 31, 2022,
as compared to $478 thousand for the three months ended March 31, 2021. The increase in Selling, general and administrative expenses
is primarily attributable to costs for professional fees and other administrative expenses in the current period associated with public
company governance requirements.
Cash and cash equivalents as of March 31, 2022
was $10.50 million as compared to $13.4 million as of December 31, 2021, primarily due to the Company's principle payments of notes
payable in the amount of approximately $2 million.
First Quarter 2022 Operational Highlights
Launched MEDAGEL ClearComfort Hydrogel Patch.
MEDAGEL patches use NEXGEL's advanced hydrogel technology to prevent and treat foot blisters by comfortably insulating the skin from
friction caused by rubbing and chafing in shoes. They are available in a variety of shapes, including a customizable sheet that allows
consumers to cut and create a perfect fit for their specific shoe needs. The product is available for sale on Amazon.com.
Launched MEDAGEL Bug Bite Relief Patch.
Made in the USA, the MEDAGEL Bug Bite Relief Patches are skin-friendly and infused with skin-calming Arnica flower and pain-reducing
Lidocaine to help reduce discomfort. The product is available for sale on Amazon.com.
Conference Call Details
Management will host a conference call and webcast
today at 4:30 p.m. Eastern Time to discuss its quarterly operational and financial results for the first quarter 2022.
| Event: | NEXGEL First Quarter 2022 Results Conference Call |
| Date: | May 12, 2022 |
| Time: | 4:30 P.M. ET |
| Live Call: | 1-877-270-2148 (U.S. Toll Free) or + 1-412-902-6510 (International) |
| Webcast: | https://services.choruscall.com/mediaframe/webcast.html?webcastid=jP97vpF5 |
For interested individuals unable to join the
conference call, a replay will be available through August 12, 2022, at + 1-877-344-7529 (U.S. Toll Free) or 1-412-317-0088 (International).
Participants must use the following code to access the replay of the call: 9940170. An archived version of the webcast will also be available
on NEXGEL's Investor Relations site: https://ir.nexgel.com/.
NEXGEL is a leading provider of ultra-gentle,
high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured
electron-beam, cross-linked hydrogels for over two decades. NEXGEL has formulated more than 200 different combinations to bring natural
ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.
Forward-Looking Statement
This press release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform
Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate,"
"estimate," "expect," "intend," "plan," "project," "prospects,"
"outlook," and similar words or expressions, or future or conditional verbs, such as "will," "should,"
"would," "may," and "could," are generally forward-looking in nature and not historical facts. These
forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results,
performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons including
the impact of the COVID-19 pandemic. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking
statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact
the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2021, including
but not limited to the discussion under "Risk Factors" therein, which the Company filed with the SEC and which may be viewed
KCSA Strategic Communications
212.896.1254 / 212.896.1254
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
212.896.1241 / 516.779.2630
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF MARCH 31, 2022 AND DECEMBER 31, 2021
(in thousands, except share and per share data)
| March 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
| ASSETS: | ||||||||
| Current Assets: | ||||||||
| Cash | $ | 10,520 | $ | 13,350 | ||||
| Accounts receivable, net | 132 | 209 | ||||||
| Inventory | 280 | 291 | ||||||
| Prepaid expenses and other current assets | 167 | 77 | ||||||
| Total current assets | 11,099 | 13,927 | ||||||
| Goodwill | 311 | 311 | ||||||
| Intangibles, net | 30 | 33 | ||||||
| Property and equipment, net | 698 | 723 | ||||||
| Operating lease - right of use asset | 1,879 | 1,926 | ||||||
| Other assets | 63 | 63 | ||||||
| Total assets | $ | 14,080 | $ | 16,983 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current Liabilities: | ||||||||
| Accounts payable | $ | 183 | $ | 254 | ||||
| Accrued expenses and other current liabilities | 57 | 62 | ||||||
| Deferred Revenue | - | - | ||||||
| Convertible notes payable | 894 | 2,037 | ||||||
| Note payable, current portion | 14 | 10 | ||||||
| Warrant liability | 449 | 318 | ||||||
| Operating lease liability, current portion | 207 | 207 | ||||||
| Total current liabilities | 1,804 | 2,888 | ||||||
| Long-Term Liabilities: | ||||||||
| Operating lease liability, net of current portion | 1,707 | 1,744 | ||||||
| Notes payable, net of current portion | 265 | 266 | ||||||
| Total long-term liabilities | 1,972 | 2,010 | ||||||
| Total liabilities | 3,776 | 4,898 | ||||||
| Commitments and Contingencies (Note 15) | ||||||||
| Preferred Stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding | - | - | ||||||
| Common Stock, par value $0.001 per share, 750,000,000 shares authorized; 5,572,234 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively | 6 | 6 | ||||||
| Additional paid-in capital | 18,946 | 18,891 | ||||||
| Accumulated deficit | (8,648 | ) | (6,812 | ) | ||||
| Total stockholders' equity | 10,304 | 12,085 | ||||||
| Total liabilities and stockholders' equity | $ | 14,080 | $ | 16,983 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND
(in thousands, except share and per share data)
| Three months ended | ||||||||
| March 31, | ||||||||
| 2022 | 2021 | |||||||
| Revenues, net | $ | 396 | $ | 267 | ||||
| Cost of revenues | 418 | 309 | ||||||
| Gross loss | (22 | ) | (42 | ) | ||||
| Operating expenses | ||||||||
| Research and development | 24 | 7 | ||||||
| Selling, general and administrative | 766 | 471 | ||||||
| Total operating expenses | 790 | 478 | ||||||
| Loss from operations | (812 | ) | (520 | ) | ||||
| Other income (expense) | ||||||||
| Interest income (expense), net | (744 | ) | (148 | ) | ||||
| Loss on debt extinguishment | (150 | ) | (25 | ) | ||||
| Debt discount costs | - | (17 | ) | |||||
| Changes in fair value of warrant liability | (130 | ) | 6 | |||||
| Total other income (expense) | (1,024 | ) | (184 | ) | ||||
| Loss before income taxes | (1,836 | ) | (704 | ) | ||||
| Income tax expense | - | - | ||||||
| Net loss | $ | (1,836 | ) | $ | (704 | ) | ||
| Net loss per common share - basic | $ | (0.33 | ) | $ | (0.25 | ) | ||
| Net loss per common share - diluted | $ | (0.33 | ) | $ | (0.25 | ) | ||
| Weighted average shares used in computing net loss per common share - basic | 5,572,234 | 2,873,008 | ||||||
| Weighted average shares used in computing net loss per common share - diluted | 5,572,234 | 2,873,008 |
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS'
FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND
(in thousands, except share data)
| Retained | ||||||||||||||||||||
| Additional | Earnings | Total | ||||||||||||||||||
| Common Stock | Paid-in | (Accumulated | Stockholders' | |||||||||||||||||
| Shares | Amount | Capital | Deficit) | Equity (Deficit) | ||||||||||||||||
| Balance, January 1, 2022 | 5,572,234 | $ | 6 | $ | 18,891 | $ | (6,812 | ) | $ | 12,085 | ||||||||||
| Stock-based compensation | - | - | 55 | - | 55 | |||||||||||||||
| Net loss | - | - | - | (1,836 | ) | (1,836 | ) | |||||||||||||
| Balance, March 31, 2022 | 5,572,234 | $ | 6 | $ | 18,946 | $ | (8,648 | ) | $ | 10,304 |
| Retained | ||||||||||||||||||||
| Additional | Earnings | Total | ||||||||||||||||||
| Common Stock | Paid-in | (Accumulated | Stockholders' | |||||||||||||||||
| Shares | Amount | Capital | Deficit) | Equity (Deficit) | ||||||||||||||||
| Balance, January 1, 2021 | 2,838,047 | $ | 3 | $ | 2,570 | $ | (2,502 | ) | $ | 71 | ||||||||||
| Stock-based compensation | - | - | 69 | - | 69 | |||||||||||||||
| Restricted stock vesting | - | - | 20 | - | 20 | |||||||||||||||
| Issuances of common stock, net of issuance costs | 101,800 | - | 285 | - | 285 | |||||||||||||||
| Warrants issued for debt issuance | - | - | (17 | ) | - | (17 | ) | |||||||||||||
| Beneficial conversion and warrant features of convertible debt | - | - | 1,276 | - | 1,276 | |||||||||||||||
| Net loss | - | - | - | (704 | ) | (704 | ) | |||||||||||||
| Balance, March 31, 2021 | 2,939,847 | $ | 3 | $ | 4,203 | $ | (3,206 | ) | $ | 1,000 |
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2022 AND
| Three Months Ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| Operating Activities | ||||||||
| Net loss | $ | (1,836 | ) | $ | (704 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 28 | 27 | ||||||
| Changes in ROU asset and operating lease liability | 10 | - | ||||||
| Share-based compensation | 55 | 90 | ||||||
| Changes in fair value of warrant liability | 130 | (6 | ) | |||||
| Amortization of deferred financing costs | 741 | 108 | ||||||
| Loss on extinguishment of debt | 150 | 25 | ||||||
| Beneficial conversion feature in excess of face value | - | 51 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 77 | (23 | ) | |||||
| Inventory | 11 | (19 | ) | |||||
| Prepaid expenses and other assets | (90 | ) | 121 | |||||
| Accounts payable | (71 | ) | (14 | ) | ||||
| Accrued expenses and other liabilities | (2 | ) | (1 | ) | ||||
| Net Cash Used in Operating Activities | (797 | ) | (345 | ) | ||||
| Investing Activities | ||||||||
| Capital expenditures | - | (267 | ) | |||||
| Net Cash Used in Investing Activities | - | (267 | ) | |||||
| Financing Activities | ||||||||
| Issuance of common stock, net of issuance costs | - | 285 | ||||||
| Proceeds from notes payable | - | 15 | ||||||
| Principle payment of notes payable | (2,033 | ) | (15 | ) | ||||
| Proceeds from notes payable (PPP) | - | 128 | ||||||
| Proceeds from convertible notes | - | 1,337 | ||||||
| Principal payment on convertible notes | - | (100 | ) | |||||
| Net Cash Provided by Financing Activities | (2,033 | ) | 1,650 | |||||
| Net Increase in Cash | (2,830 | ) | 1,038 | |||||
| Cash - Beginning of period | 13,350 | 32 | ||||||
| Cash - End of period | $ | 10,520 | $ | 1,070 | ||||
| Supplemental Disclosure of Cash Flows Information | ||||||||
| Cash paid during the year for: | ||||||||
| Interest | - | - | ||||||
| Taxes | - | - | ||||||
| Supplemental Non-cash Investing and Financing activities | ||||||||
| Fair value of beneficial conversion and warrant features of Convertible Notes Payable | $ | - | $ | 1,276 | ||||
| Original issue discounts recognized on Convertible Notes Payable | $ | - | $ | 343 | ||||
| Warrants issued for debt and equity financing costs | $ | - | $ | 130 |